Scott Braunstein, Marinus CEO

Af­ter strug­gling with its sole drug for years, Mar­i­nus rides pos­i­tive da­ta to a com­mer­cial­iza­tion deal in Eu­rope

Af­ter a se­ries of painful set­backs, Mar­i­nus had a re­birth of sorts last year when it of­fered a pos­i­tive late-stage pre­view of its sole drug, ganax­olone, in a ge­net­ic dis­or­der that caus­es ear­ly-on­set epilep­sy. Now, CEO Scott Braun­stein is rid­ing that suc­cess to an NDA sub­mis­sion and a col­lab­o­ra­tion with the Finnish phar­ma com­pa­ny Ori­on to com­mer­cial­ize the can­di­date in Eu­rope.

Ori­on is putting down around $30 mil­lion up­front (€25 mil­lion) and $115 mil­lion in biobucks (€97 mil­lion) for ex­clu­sive rights to mar­ket both the oral and IV for­mu­la­tions of ganax­olone in the EU, UK and Switzer­land for the treat­ment of CD­KL5 de­fi­cien­cy dis­or­der (CDD), tuber­ous scle­ro­sis com­plex (TSC) and re­frac­to­ry sta­tus epilep­ti­cus (RSE).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.